Evidence map›Paper›PMID 34245429›Full record

ArticleImmunologic research2021

Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies.

Massimo Radin, Alice Barinotti, Silvia Grazietta Foddai, Irene Cecchi, Elena Rubini, Dario Roccatello, Elisa Menegatti, Savino Sciascia

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunologic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Massimo RadinCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy. massimo.radin@unito.it.
Alice BarinottiCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
Silvia Grazietta FoddaiCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
Irene CecchiCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
Elena RubiniCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
Dario RoccatelloCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
Elisa MenegattiCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
Savino SciasciaCenter of Research of Immunopathology and Rare Diseases- Coordinating Center of Piedmont and Aosta Valley Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
University of Turin · ITOspedale San Giovanni Bosco · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interest of extra-criteria antiphospholipid antibodies is growing, especially in patients negative for conventional antibodies. In this study we aimed to assess the clinical utility of anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) testing in patients negative for Beta2-Glycoprotein 1(β2GPI)-dependent tests, for identifying antiphospholipid syndrome (APS) patients that developed cerebrovascular events (CVE). When screening APS patients attending our center, out of 119 aPS/PT IgG/IgM-positive patients, thus patients negative for aβ2GPI and aCL, 42 patients (35%) tested negative for β2GPI-dependent tests and were tested with thrombin generation assay (TGA). Ten patients (24%), with isolated aPS/PT IgG/IgM, had a history of CVE. Lupus anticoagulant (LA)-positive test was more frequently observed in patients with CVE (8/22 vs. 2/20; p = 0.045). Out of the 10 patients who experienced CVE, 3 patients were aPS/PT IgG positive (all LA positive), and 8 patients were aPS/PT IgM positive (6/8 LA positive). One patient was positive for both aPS/PT IgG and IgM. LA-positive patients had only high titers of aPS/PT IgG/IgM, all of them being ≥ 80 U/ml, while the 2 LA-negative patients were aPS/PT IgM positive with medium titers [40-60 U/ml]. LA-positive patients had significantly altered TGA profile when compared to those who were LA negative, considering all TGA parameters. LA-positive patients had significantly higher tLag (8.4 ± 3.3 min vs. 6.6 ± 1.8 min; p = 0.046), higher tPeak (14 ± 4.3 min vs. 11 ± 2.7 min; p = 0.015) and lower Peak (207 ± 152 nM vs. 356.3 ± 104.7 nM; p < 0.001) and lower AUC (2109.7 ± 1006.9 nM vs. 2772.5 ± 776.8 nM; p = 0.033). The use of aPS/PT might be of help in identifying patients with CVE and APS, as also confirmed by TGA testing.

Indexed as

AdultAntiphospholipid Syndromebeta 2-Glycoprotein ICerebrovascular DisordersFemaleHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedPhosphatidylserinesProthrombinbeta 2-Glycoprotein IImmunoglobulin GImmunoglobulin MPhosphatidylserinesProthrombinAnti-phosphatidyl-serine/prothrombin antibodiesAntiphospholipid antibodiesAntiphospholipid syndromeCerebrovascular eventsStrokeThrombosis

Identifiers

PMID34245429
PMCPMC8342389
OpenAlexW3178748373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.